By Pooja Nawathe, MD; Myriam AlmeidaJones, MD; Christina Wheelwright, NP; Evan M. Zahn, MD
Introduction
Transcatheter closure of Secundum Atrial Septal Defects (ASD) is well-documented to be an effective alternative to surgical ASD closure.1 The overall complication rate of transcatheter ASD occlusion has been found to be significantly less than that of surgery.2 There have been several reviews of transcatheter ASD closure devices 2-4 discussing rare, but major adverse events, such as device embolization, cardiac perforation, and thromboembolic complications. We report a case of severe hemolytic anemia after transcatheter ASD closure possibly related to the interface between the device surface and a previously present high velocity jet of mitral regurgitation. The hemolysis resolved quickly following replacement of the initial ASD occluder with a device with different surface characteristics.
To read the full article, please go to the September 2018 Issue of CCT, where it was originally published.